Disruption of Clever-1 for Novel Anticancer Immunotherapy
Pysyvä osoite
Verkkojulkaisu
DOI
Tiivistelmä
The progression of cancer is dependent on the quality of the immune response elicited by the tumour. Typically, proinflammatory immune responses restrain and anti-inflammatory immune responses promote the progression of cancer. Thee immunosuppression caused by anti-inflammatory leukocytes, such as regulatory T cells and alternatively activated macrophages, is a major obstacle in the successful treatment of cancer.
Clever-1 is a multifunctional protein expressed by a subset of human monocytes and alternatively activated, or M2, macrophages. In these macrophages, Clever-1 is involved in receptor-mediated endocytosis, intracellular sorting, and transcytosis. Clever-1 is also expressed on lymphatic and vascular endothelia, where it mediates the trafficking of leukocytes from the lymph or blood into tissues. Lymphatics and macrophages expressing Clever-1 have been detected in human cancers, and high numbers of Clever-1-positive macrophages correlate with poorer prognoses in advanced colorectal cancer.
By using specific antibodies to interfere with the function Clever-1, we have recently demonstrated that Clever-1 antibody treatment limits the progression of cancer in animal models of melanoma and lymphoma. According to these results, the antibody-mediated interference of Clever-1 both before and after cancer cell implantation limits tumour growth and metastasis. However, the molecular mechanisms by which Clever-1 regulates the phenotype and function of tumour-associated macrophages during this process are very poorly understood.
The data presented in this master’s thesis reveal novel molecular mechanisms employed by Clever-1 to regulate the function of M2 macrophages and suggest that Clever-1 antibody treatment may have immunotherapeutic potential in the treatment of breast cancer. According to the obtained results, Clever-1 promoted intracellular signal transduction through the anti-inflammatory mTORC1 complex in M2 macrophages. In accordance, the antibody-mediated interference of Clever-1 induced a proinflammatory response from M2 macrophages by increasing the production and secretion of TNF-alpha, a major mediator of inflammation. Furthermore, combinatorial antibody-mediated interference of Clever-1 and the immune checkpoint protein PD-1 decreased the relative amount of anti-inflammatory tumour-associated macrophages, thereby likely promoting a more proinflammatory milieu within the tumour microenvironment. Additionally, combinatorial Clever-1 and PD-1 antibody treatment appeared to limit tumour growth and metastasis also in a mouse model of triple-negative breast cancer.
Kuvaus
Siirretty Doriasta